Correction

This article refers to:

Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM)

Article title: Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM)

Authors: Nakamura Ichiro, Maegawa Hiroshi, Tobe Kazuyuki, Uno Satoshi.

Journal: EXPERT OPINION ON PHARMACOTHERAPY

Bibliometrics: Volume 22, Number 03, pages 373-387

DOI: https://doi.org/10.1080/14656566.2020.1817388

When this article was first published in an issue, there was an error in Table 4 which has been now corrected as below in the original article.

Table 4. Adverse drug reactions of special interest

	This study (safety analysis set, n=11,051)			Pre-approval clinical trials, n=1,669 (%)
	Total,n (%)	Serious,n (%)	Non-serious,n (%)
All ADRs	2,129 (19.27)	210 (1.90)	1,993 (18.03)	(32.9)
ADRs of special interest
Hypoglycemia	57 (0.52)	4 (0.04)	53 (0.48)	(1.4)
Genital infection	161 (1.46)	3 (0.03)	158 (1.43)	(2.0)
Urinary tract infection	170 (1.54)	9 (0.08)	161 (1.46)	(1.8)
Polyuria/pollakiuria	612 (5.54)	1 (0.01)	611 (5.53)	(10.0)
Volume depletion-related events, including dehydration	243 (2.20)	14 (0.13)	232 (2.10)	(4.5)
Renal disorder	191 (1.73)	7 (0.06)	184 (1.67)	(4.6)
Hepatic disorder	133 (1.20)	6 (0.05)	129 (1.17)	(1.0)
Fracture	4 (0.04)	2 (0.02)	2 (0.02)	(0.0)
Malignant tumor	51 (0.46)	44 (0.40)	7 (0.06)	(0.2)
Cardiovascular disease	67 (0.61)	46 (0.42)	22 (0.20)	(1.0)
Cerebrovascular disease	48 (0.43)	37 (0.33)	11 (0.10)	(0.2)
Skin complications	198 (1.79)	4 (0.04)	194 (1.76)	(3.5)
Ketoacidosis, events related to ketone-body increase	7 (0.06)	2 (0.02)	5 (0.05)	(0.7)
Lower limb amputation	0	0	0	(0.0)

Abbreviation: ADRs, adverse drug reactions. Note: No. of patients (%) is shown.